Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Sawyer SL, Hartley T, Dyment DA, Beaulieu CL, Schwartzentruber J, Smith A, et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet. 2016;89:275–84.
2. Bauskis A, Strange C, Molster C, Fisher C. The diagnostic odyssey: insights from parents of children living with an undiagnosed condition. Orphanet J Rare Dis. 2022;17:233.
3. Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008;372:889–90.
4. Kanatani Y, Tomita N, Sato Y, Eto A, Omoe H, Mizushima H. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir (Tokyo). 2017;57:1–7.
5. Act on Medical Care for Patients with Intractable Diseases, Act No. 50 of May 30, 2014, Government of Japan. Available from: https://www.japaneselawtranslation.go.jp/ja/laws/view/3363.